Valery V. Belakhov

Valery V. Belakhov

Auto-generated profile, based on publicly available information

Valery V. Belakhov

Schulich Faculty of Chemistry, Technion – Israel Institute of Technology, Haifa, Israel

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
INIgor Nudelman
Igor Nudelman
ARAnnie Rebibo-Sabbah
Annie Rebibo-Sabbah
MCMarina Cherniavsky
Marina Cherniavsky
VBValery Belakhov
Valery Belakhov
MHMariana Hainrichson
Mariana Hainrichson
TBTimor Baasov
Timor Baasov

1 April 2014 in American Journal of Respiratory Cell and Molecular Biology
Verified
Journal Article
Closed access
XXXiaojiao Xue
Xiaojiao Xue
VMVenkateshwar Mutyam
Venkateshwar Mutyam
LTLiping Tang
Liping Tang
SBSilpak Biswas
Silpak Biswas
MDMing Du
Ming Du
SRSteven M. Rowe
Steven M. Rowe
New drugs are needed to enhance premature termination codon (PTC) suppression to treat the underlying cause of cystic fibrosis (CF) and other diseases caused by nonsense mutations. We tested new synthetic aminoglycoside derivatives expressly developed for PTC suppression in a series of complementary CF models. Using a dual-luciferase reporter system containing the four most prevalent CF transmembrane conductance regulator (CFTR) nonsense mutations (G542X, R553X, R1162X, and W1282X) within their local sequence contexts (the three codons on either side of the PTC), we found that NB124 promoted the most readthrough of G542X, R1162X, and W1282X PTCs. NB124 also restored full-length CFTR expression and chloride transport in Fischer rat thyroid cells stably transduced with a CFTR–G542XcDNA transgene, and was superior to gentamicin and other aminoglycosides tested. NB124 restored CFTR function to roughly 7% of wild-type activity in primary human bronchial epithelial (HBE) CF cells (G542X/delF508), a highly relevant preclinical model with endogenous CFTR expression. Efficacy was further enhanced by addition of the CFTR potentiator, ivacaftor (VX-770), to airway cells expressing CFTR PTCs. NB124 treatment rescued CFTR function in a CF mouse model expressing a human CFTR-G542X transgene; efficacy was superior to gentamicin and exhibited favorable pharmacokinetic properties, suggesting that in vitro results translated to clinical benefit in vivo. NB124 was also less cytotoxic than gentamicin in a tissue-based model for ototoxicity. These results provide evidence that NB124 and other synthetic aminoglycosides provide a 10-fold improvement in therapeutic index over gentamicin and other first-generation aminoglycosides, providing a promising treatment for a wide array of CFTR nonsense mutations.

1 October 2003 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
KHKlaus Hövel
Klaus Hövel
DSDalia Shallom
Dalia Shallom
Karsten NiefindKarsten Niefind
Karsten Niefind
VBValery Belakhov
Valery Belakhov
GSGil Shoham
Gil Shoham
DSDietmar Schomburg
Dietmar Schomburg
High‐resolution crystal structures of α‐l‐arabinofuranosidase from Geobacillus stearothermophilus T‐6, a family 51 glycosidase, are described. The enzyme is a hexamer, and each monomer is organized into two domains: a (β/α)8‐barrel and a 12‐stranded β sandwich with jelly‐roll topology. The structures of the Michaelis complexes with natural and synthetic substrates, and of the transient covalent arabinofuranosyl—enzyme intermediate represent two stable states in the double displacement mechanism, and allow thorough examination of the catalytic mechanism. The arabinofuranose sugar is tightly bound and distorted by an extensive network of hydrogen bonds. The two catalytic residues are 4.7 Å apart, and together with other conserved residues contribute to the stabilization of the oxocarbenium ion‐like transition state via charge delocalization and specific protein—substrate interactions. The enzyme is an anti ‐protonator, and a 1.7 Å electrophilic migration of the anomeric carbon takes place during the hydrolysis.

20 March 2009 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VPVarvara Pokrovskaya
Varvara Pokrovskaya
VBValery Belakhov
Valery Belakhov
MHMariana Hainrichson
Mariana Hainrichson
SYSima Yaron
Sima Yaron
TBTimor Baasov
Timor Baasov

10 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KKKim Keeling
Kim Keeling
DWDan Wang
Dan Wang
YDYanying Dai
Yanying Dai
SMSrinivasan Murugesan
Srinivasan Murugesan
BCBalachandra Chenna
Balachandra Chenna
DBDavid M. Bedwell
David M. Bedwell
Nonsense suppression therapy is an approach to treat genetic diseases caused by nonsense mutations. This therapeutic strategy pharmacologically suppresses translation termination at Premature Termination Codons (PTCs) in order to restore expression of functional protein. However, the process of Nonsense-Mediated mRNA Decay (NMD), which reduces the abundance of mRNAs containing PTCs, frequently limits this approach. Here, we used a mouse model of the lysosomal storage disease mucopolysaccharidosis I-Hurler (MPS I-H) that carries a PTC in the Idua locus to test whether NMD attenuation can enhance PTC suppression in vivo. Idua encodes alpha-L-iduronidase, an enzyme required for degradation of the glycosaminoglycans (GAGs) heparan sulfate and dermatan sulfate. We found that the NMD attenuator NMDI-1 increased the abundance of the PTC-containing Idua transcript. Furthermore, co-administration of NMDI-1 with the PTC suppression drug gentamicin enhanced alpha-L-iduronidase activity compared to gentamicin alone, leading to a greater reduction of GAG storage in mouse tissues, including the brain. These results demonstrate that NMD attenuation significantly enhances suppression therapy in vivo.

1 June 2010 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
INIgor Nudelman
Igor Nudelman
DGDana Glikin
Dana Glikin
BSBoris Smolkin
Boris Smolkin
MHMariana Hainrichson
Mariana Hainrichson
VBValery Belakhov
Valery Belakhov
TBTimor Baasov
Timor Baasov